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Abstract
Background: Recent investigations suggest role(s) of human arylamine N-acetyltransferase 1 (NAT1) in breast
cancer. Rat NAT2 is orthologous to human NAT1 and the gene products are functional homologs. We conducted in
vivo studies using F344.WKY-Nat2rapid/slow rats, congenic at rat Nat2 for high (rapid) and low (slow) arylamine
N-acetyltransferase activity, to assess a possible role for rat NAT2 in mammary tumor susceptibility.
Methods: Mammary carcinogens, methylnitrosourea (MNU) and 7,12-dimethylbenzanthracene (DMBA) neither of
which is metabolized by N-acetyltransferase, were administered to assess mammary tumors. MNU was administered
at 3 or 8 weeks of age. DMBA was administered at 8 weeks of age. NAT2 enzymatic activity and endogenous
acetyl-coenzyme A (AcCoA) levels were measured in tissue samples and embryonic fibroblasts isolated from the
congenic rats.
Results: Tumor latency was shorter in rapid NAT2 rats compared to slow NAT2 rats, with statistical significance for
MNU administered at 3 and 8 weeks of age (p = 0.009 and 0.050, respectively). Tumor multiplicity and incidence
were higher in rapid NAT2 rats compared to slow NAT2 rats administered MNU or DMBA at 8 weeks of age (MNU,
p = 0.050 and 0.035; DMBA, p = 0.004 and 0.027, respectively). Recombinant rat rapid-NAT2, as well as tissue
samples and embryonic fibroblasts derived from rapid NAT2 rats, catalyzed p-aminobenzoic acid N-acetyl transfer
and folate-dependent acetyl-coenzyme A (AcCoA) hydrolysis at higher rates than those derived from rat slow-NAT2.
Embryonic fibroblasts isolated from rapid NAT2 rats displayed lower levels of cellular AcCoA than slow NAT2 rats
(p < 0.01).
Conclusions: A novel role for rat NAT2 in mammary cancer was discovered unrelated to carcinogen metabolism,
suggesting a role for human NAT1 in breast cancer.
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Background
Human arylamine N-acetyltransferase 1 (NAT1) is a
cytosolic isoenzyme responsible for the N-acetylation of
arylamine xenobiotics, including environmental and occu-
pational carcinogens such as 4-aminobiphenyl (ABP) [1].
NAT1 is located on the short arm of chromosome 8
(8p22) and is expressed in nearly all human tissues [2, 3].
NAT1 catalyzes both O-acetylation and N-acetylation.
One role for NAT1 in carcinogenesis is its ability to bio-
transform arylamine procarcinogens to active carcinogens
[4]. Recent findings in vitro suggest that NAT1 activity
level also may influence cancer cell proliferation and
survival [5–8].
NAT1 activity is modified by genetic polymorphism,
but also can be regulated by microRNA, epigenetic,
and/or translational and post-translational control fea-
tures [9–12]. NAT1 transcript levels are regulated by
extracellular stimuli acting on glucocorticoid receptor
or androgen receptor [13, 14]. Exposure to NAT1 sub-
strates can increase NAT1 degradation [11, 12]. Some
polymorphisms in humans destabilize the enzyme, lead-
ing to greater polyubiquitin-dependent degradation
[11]. NAT1*10, the most common haplotype, is associ-
ated with increased NAT1 activity in human bladder
[15], colon [16], and liver [17]. NAT1*10 has been asso-
ciated with higher risk of developing cancers of the
breast [18], colon/rectum [19, 20], lung [21], pancreas
[22], and urinary bladder [23]. However, other studies
have reported no association between NAT1*10 and
cancer risk [24, 25].
Rat arylamine N-acetyltransferases are similar in se-
quence and function to human N-acetyltransferases
[26–28]. Rat NAT2 and human NAT1 active sites both
contain Phe125, Arg127, and Tyr129, consistent with
their similar arylamine substrate selectivity [28]. The C-
terminal undecapeptide, which is involved in controlling
acetyl-coenzyme A (AcCoA) hydrolysis [29], is 100% iden-
tical when comparing rat NAT2 and human NAT1.
Fischer 344 (F344) and Wistar Kyoto (WKY) inbred rat
strains have been characterized as rapid and slow NAT2
acetylators, respectively [30, 31]. Slow acetylator WKY in-
bred rats are homozygous for a Nat2 allele that contains
four single nucleotide polymorphisms (SNPs): G361A
(Val121→ Ile), G399A (synonymous), G522A (synonymous),
and G796A (Val266 → Ile), compared to the F344 strain
rapid-acetylator Nat2 allele [32]. Our laboratory con-
structed and characterized congenic F344.WKY rats with
high (rapid) and low (slow) NAT2 activities [33].
In the current study, we utilized rapid (F344.WKY-
Nat2rapid) and slow (F344.WKY-Nat2slow) acetylator rat
strains to investigate mammary cancer risk following the
administration of methylnitrosourea (MNU) or 7,12-
dimethylbenzanthracene (DMBA), neither of which is
biotransformed by rat NAT2 [34–37]. The results of this
study provide new evidence and insight into a role of rat
NAT2 and, by analogy, human NAT1 in breast cancer
susceptibility.
Methods
Rapid and slow acetylator rats congenic at the Nat2 locus
Rapid and slow acetylator Nat2 congenic Fischer 344
(F344.WKY) rats were housed in the University of
Louisville animal facility and the experiments were
reviewed and approved by the University’s Institutional
Animal Care and Use Committee. The construction of
rapid and slow acetylator Nat2 congenic rats was previ-
ously reported [33]. Briefly, F344 (homozygous Nat2
rapid) males were mated to WKY (homozygous Nat2
slow) females to produce the obligate heterozygous F1
generation. F1 females were then backcrossed with F344
males. Heterozygous acetylator female progeny from
each successive backcross were identified by rat Nat2
genotype and were mated with F344 rapid acetylator
males. After ten generations of backcrossing, heterozygous
acetylator brother/sister progeny were mated to produce
the homozygous rapid and slow acetylator congenic rat
Nat2 lines. The congenic F344.WKY rats have been
confirmed for rapid and slow phenotypic differences in
activity across multiple tissues and with different
substrates [33].
Methylnitrosourea administration
Forty-two female rapid acetylator congenic rats and
thirty-four female slow acetylator congenic rats, at
3 weeks of age, were administered methylnitrosourea
(MNU; CAS#: 684-93-5)(Ash-Stevens, Detroit, MI) by a
single intraperitoneal (IP) injection of 50 mg/kg (10 mg/
ml) solution dissolved in saline pH 5.0, acidified with
glacial acetic acid (Fig. 1) [38–40]. Six rapid and six slow
acetylator control female rats were injected with vehicle.
During the twenty-three week experiment, one rapid
(17 weeks) and two slow acetylator rats (18 and
18 weeks) were euthanized due to tumor burden and/or
size. These data were incorporated into the statistical
analysis.
Twenty-four rapid acetylator female congenic rats and
thirty-three slow acetylator female congenic rats, at
8 weeks of age, were administered MNU by a single IP
injection of 50 mg/kg (10 mg/ml) as above (Fig. 1).
Three rapid and four slow acetylator control female rats
were injected with vehicle. During the study one rapid
female acetylator rat was euthanized (16 weeks) because
of tumor burden and/or size. This sample was included
in the statistical analysis.
7,12-dimethylbenzanthracene administration
Twenty-eight rapid acetylator female congenic rats and
thirty-three slow acetylator female congenic rats were
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given a single dose of 7,12-dimethylbenzanthracene dis-
solved in sesame seed oil (DMBA; CAS#: 57-97-6)(Acros
Organics, New Jersey, USA) (65 mg/kg) by oral gavage
at 8 weeks of age (Fig. 1) [41, 42]. Three rapid and three
slow acetylator control female rats were injected with ve-
hicle. During the study four rapid female acetylator rats
were euthanized (14, 17, 20, and 21 weeks) because of
weight loss or tumor burden issues. Additionally six slow
acetylator females were euthanized (9, 17, 14, 20, 21, and
21 weeks) for weight loss or tumor burden issues. These
data were still utilized for statistical analysis.
Weekly monitoring of animal weight and palpable
mammary tumors
Rats were weighed weekly following carcinogen adminis-
tration. Rats that displayed bradykinesia/fatigue, a tumor
size =10% of body weight, or tumors that were ulcerated
(any break in skin observed) were euthanized. Rats were
palpated weekly. The number of weeks post-carcinogen
exposure of first palpable mammary tumor was recorded.
Mammary tissue and tumor collection
Twenty-three weeks after administration of a carcino-
gen, rats were euthanized by CO2 asphyxiation followed
by cervical dislocation. The rats were immediately
dissected to count mammary tumors that were ≥3 mm
in any direction, collect samples, and record any abnor-
malities. Mammary tumor and adjacent mammary-
tissues were removed and fixed in 10% neutral buffered
formalin.
Pathology
Tissue samples described above were processed and
stained by the Special Procedure Laboratory at the
University of Louisville. In brief, tissue was paraffin em-
bedded and sections cut at 5 μm. Sections were stained
using hematoxylin and eosin (H&E). H&E stained slides
were evaluated and categorized, based on histomorphol-
ogy, into the following groups: Normal, Benign, Low
Grade Carcinoma In Situ (CIS), Intermediate Grade CIS,
High Grade CIS and Invasive Carcinoma. If a mammary
tumor demonstrated multiple features of more than one
category, the most malignant category was used for classi-
fication. Rats with multiple tumors were categorized by
the most severe classification. These evaluations and clas-
sifications were blind to rat treatment and phenotype.
Rapid and slow acetylator rat NAT2 recombinant
expression and enzymatic activity
Recombinant rapid and slow acetylator rat NAT2 proteins
were expressed in JM105 E. coli as described [32, 43].
Total bacterial lysate protein concentration was deter-
mined for each expression using the Bio-Rad protein assay
kit (Bio-Rad, Hercules, CA). Bacterial lysates were assayed
for N-acetylation of para-aminobenzoic acid (PABA) and
folate-dependent AcCoA hydrolysis.
For determination of PABA N-acetylation activity,
lysates (in triplicate) were incubated with 1 mM AcCoA
and 300 μM PABA for 10 min at 37 °C, and the reaction
was stopped by addition of 1/10 volume of 1 M acetic
acid. The reaction tubes were centrifuged to remove
Fig. 1 Experimental design for chemical-induced tumor experiments. Top shows the dosing of MNU at 3 weeks of age. The middle displays the
dosing of MNU at 8 weeks of age. The bottom depicts the dosing of DMBA at 8 weeks of age
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precipitated protein, and supernatant was injected onto
a LiChrospher 100 RP-18 (125 mm X 4 mm; 5 μm)
reverse-phase column. Reactants and products were sep-
arated by high-performance liquid chromatography
(HPLC)(Beckman Coulter, Fullerton, CA). N-Acetyl-
PABA product was quantitated by its absorbance at
280 nm as described [43].
Bacterial lysates were assayed for folate-dependent
AcCoA hydrolytic activity as reported [43]. In brief, ly-
sates (in triplicate) were incubated with 500 μM
AcCoA in the presence or absence of 300 μM folate
for 10 min at 37 °C, and the reaction was quenched by
adding 1/10 volume of perchloric acid (15% w/v). The
precipitated protein was removed by centrifugation
and the supernatant was injected onto a C18 reverse-
phase HPLC column (250 mm X 4 mm; 5 μm). Reac-
tants and products were separated and quantitated by
HPLC. Separation of CoA, acetyl CoA, and folate was
achieved using a linear gradient of 100% 55 mM so-
dium phosphate (NaH2PO4) pH 4.0: 0% methanol to
0% 55 mM sodium phosphate pH 4.0: 100% methanol
over 20 mins and was quantitated by absorbance at
260 nm. The amounts of CoA produced in the minus
folate reactions were subtracted from reactions con-
taining folate to determine folate-dependent hydroly-
sis. Control reactions without the addition of protein
lysate also were included. The limit of detection for
CoA was 0.05 nmoles/min/mg protein.
Rapid and slow congenic rat tissue lysate preparation and
enzymatic activity
Liver, lung, colon, and mammary tissues were collected
from 8 week old female rapid and slow NAT2 congenic
rats. Tissues were homogenized in 20 mM sodium phos-
phate (pH 7.4), 1 mM EDTA, 0.2% triton X-100, 1 mM
dithiothreitol, 100 μM phenylmethanesulfonyl fluoride,
10 μg/ml aprotinin, and 1 μM pepstatin. Homogenates
were centrifuged at 15,000 x g for 10 min, and aliquots
of supernatants were stored at −80 °C until used. Protein
concentrations were determined using the Bio-Rad pro-
tein assay kit.
To measure PABA N-acetylation activity, reactions
containing tissue lysate (<2 mg of protein/ml), 300 μM
PABA and 1 mM AcCoA were incubated at 37 °C for
10 min. Reactions were terminated by the addition of 1/
10 volume of 1 M acetic acid. Activity was quantified by
HPLC as described above.
To measure folate-dependent AcCoA hydrolytic activ-
ity, reactions containing tissue lysate (<2 mg of protein/
ml), 300 μM folate and 500 μM AcCoA were incubated
at 37 °C for 10 min. Reactions were terminated by the
addition of 1/10 volume of perchloric acid (15% w/v).
Activity was quantified by HPLC as described above.
Rat embryonic fibroblasts isolation
Rat embryonic fibroblasts (REFs) were isolated from
congenic rats by adapting procedures described previ-
ously for mouse embryonic fibroblasts [44]. Dams were
euthanized by CO2 asphyxiation and cervical dislocation
on E13.5 (13.5 days post copulation) and embryos re-
moved by Caesarean section. Embryonic brain tissue and
organs were removed. The resultant tissue was dissoci-
ated by gentle enzymatic digestion [0.05% trypsin (w/v)
for 15 mins] and cells were plated into 10 cm dishes
(one embryo per dish) in DMEM (Dulbecco’s modified
Eagle’s medium; high glucose, Lonza, Walkersville, MD,
USA) supplemented with 10% FBS (fetal bovine serum),
2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml
streptomycin and 0.25 mg/ml amphotericin. Passaging
was by cell dissociation from plates [0.05% trypsin (w/v)
for 15 mins] and re-plating 5 × 105 cells on fresh 10 cm
dishes. Resulting REF cell lines at passage 4 were charac-
terized for their PABA N-acetylation activities as de-
scribed above.
REFs endogenous cellular AcCoA concentration
measurements
Endogenous acetyl-CoA levels within REFs were deter-
mined by HPLC. On passage 4, the REFs were plated at
5 × 105 per plate and allowed to grow for 96 h. After
96 h, media were aspirated from each plate, and washed
with 5 ml phosphate-buffered saline (PBS). Then cells
were gently dissociated from the plate with 0.5 ml tryp-
sin [0.05% (w/v) for 15 mins]. Cells were suspended in
4 ml of diluted complete media (20% medium and 80%
PBS). Aliquots of 0.5 ml were used to count the number
of cells per ml. In the subsequent steps all cells and ly-
sates were kept on ice or in 4 °C conditions. Collected
cells were washed with ice cold PBS, and transferred to
a 1.5 ml microcentrifuge tubes. The suspended cells
were collected by centrifugation and the supernatants
discarded. Having removed any residual PBS, the cells
were suspended in 100 μl of ice-cold 5% 5-sulfosalicylic
acid with a 1 ml BD Insulin Syringe with permanently
attached 28 gauge needle (BD Franklin Lakes, NJ, USA).
The cellular lysate was then centrifuged at 13,000 x g for
10 min. Supernatant was filtered through a syringe filter
(13 mm, 0.20 μm pore size). Filtrate was collected and
separated on a C18 reverse-phase HPLC column
(250 mm × 4 mm; 5 μm pore size). HPLC separation
and quantitation of AcCoA was achieved using the same
method described above for folate-dependent AcCoA
hydrolysis.
Statistics
Weights were compared over time by a two-way analysis
of variance followed by Bonferroni post hoc test. Latency
and incidence of first palpable mammary tumors over
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time were tested by logrank (Mantel-Cox) test. Mann-
Whitney tests were used to compare mammary tumor
multiplicity. Terminal tumor incidence was tested by a
Fischer’s exact test. Enzymatic activities and endogen-
ous AcCoA concentrations were compared by unpaired
t-tests. All statistical tests were done using Prism soft-
ware by GraphPad (La Jolla, CA). Data are displayed
and presented as the average ± standard error of mean
(SEM) for each respective group.
Results
Weight gain
Rapid and slow acetylator congenic rats administered ve-
hicle at either 3 or 8 weeks demonstrated normal weight
gain. Initially, all MNU-treated rats experienced hindered
weight gain post administration, but then recovered to a
rate of weight gain similar to vehicle-treated rats. MNU-
treated rats never reached the same weight as the vehicle-
treated counterparts (Fig. 2). No statistically significant
(p > 0.05) differences in weight gain were noted between
MNU-treated rapid and slow acetylator congenic rats.
DMBA-treated rats displayed no initial hindrance in
weight gain; however, during the time following DMBA
administration, DMBA-treated rats tended to have lower
body weight than vehicle-treated rats (Fig. 2). No statisti-
cally significant (p > 0.05) differences in weight gain
were noted between DMBA-treated rapid and slow acet-
ylator congenic rats.
Palpable mammary tumor latency and incidence
As shown in Fig. 3, rapid acetylator congenic rats had a
significantly (p<0.05) shorter latency for development of
their first palpable mammary tumor compared to slow
acetylator NAT2 congenic rats after administration of
MNU in females treated at either 3 or 8 weeks of age.
DMBA-treated rapid acetylator rats displayed a higher
tumor incidence over the course of weeks than DMBA-
treated slow acetylator rats, although logrank test analysis
provides a p-value (p = 0.065) slightly greater than our
established p-value threshold of significance (p = 0.050).
Terminal mammary tumor incidence and multiplicity
As shown in Table 1, female congenic rats, administered
MNU at 3 weeks of age, developed tumors in 66.7% of
the rapid acetylator congenic rats with an average
1.00 ± 0.17 tumors per rat. In contrast, tumors were
found in 52.9% of slow acetylator congenic rats with an
average of 0.67 ± 0.12 tumors per rat. These mammary
tumor incidence and multiplicity results were not signifi-
cantly different between rapid and slow acetylator rats
administered MNU at 3 weeks of age.
As shown in Table 1, female congenic rats administered
MNU at 8 weeks of age, developed mammary tumors in
41.6% of rapid acetylators with 0.50 ± 0.14 average tumors
per rat. Slow acetylators developed mammary tumors in
15.2% of those given MNU, with 0.24 ± 0.12 tumors per
rat. Thus, rapid acetylator rats exhibited significantly
higher mammary tumor incidence (p = 0.035) and multi-
plicity (p = 0.050) compared to slow acetylator rats.
No other tissue/organ tumors besides mammary tumors
were observed in either MNU- or vehicle-treated rats. A
few rats displayed discoloration of the eyes, thought to be
an onset of cataracts. Cataracts and retinal degradation
can occur in rats following MNU administration [45].
As shown in Table 1, female congenic rats exposed to
DMBA developed mammary tumors in 76.0% of rapid
acetylators with 1.20 ± 0.16 average tumors per rat. Slow
acetylators developed mammary tumors in 43.3% of
those given DMBA, with 0.57 ± 0.14 tumors per rat.
Rapid acetylator rats had significantly higher mammary
Fig. 2 Weekly body mass (mean grams ± SEM) of rapid and slow acetylator Nat2 congenic rats post administration of specified carcinogen or
vehicle control. In all three panels squares represent rapid acetylator and circles represent slow acetylator congenic rats. Filled-shapes represent
vehicle-treated and unfilled-shapes represent. MNU or DMBA-treated. a Weights for rats treated with MNU at 3 weeks of age. The difference
between weights of the vehicle-treated and MNU-treated is statistically significant by two-way ANOVA with Bonferroni post hoc test (p < 0.05).
b Weights for rats treated with MNU at 8 weeks of age. The weights of the vehicle-treated and MNU treated rats were statistically significant by
two-way ANOVA with Bonferroni post hoc test (p < 0.05). c Weights for rats administrated DMBA at 8 weeks of age. The weights of the vehicle-
treated and DMBA-treated rats were not statistically significant by two-way ANOVA with Bonferroni post hoc test (p > 0.05). In all panels, weights
of MNU/DMBA-treated rats were not significantly different between rapid and slow NAT2 acetylator rat strains
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tumor incidence (p = 0.027) and multiplicity (p = 0.004)
compared to slow acetylator rats. No other tissue/organ
tumors besides mammary tumors were observed in
DMBA- or vehicle-treated rats.
Pathology
A majority of the mammary tumors that developed in
carcinogen-treated rats were classified as non-invasive
(Fig. 4). More tumors classified as benign were noted in
rats administered MNU at 3 weeks compared to 8 weeks
of age (15% and 0%, respectively).
Among the rapid and slow congenic rat strains admin-
istrated MNU at 3 weeks of age, ~11% of tumors were
classified as invasive carcinomas in the rapid acetylators
(3/28) versus none in the slow acetylators (0/18). Low
grade CIS tumors were the most common histomorpho-
logical classification of tumors in both rapid and slow
rat Nat2 congenic strains.
Rats administered MNU at 8 weeks of age exhibited
similar percentages of mammary tumors classified as
low grade CIS in rapid (5/10) and slow (2/5) acetylators.
Mammary tumors classified as high grade CIS tumors
were observed in 3 rapid acetylator congenic rats (3/10),
and the only tumor classified as invasive was found in
one slow acetylator rat (1/5).
In general, rats administered DMBA displayed a very
similar distribution pattern of tumor pathology. The
rapid NAT2 congenic rats had more benign tumors (4/
19 or 21%) than slow NAT2 congenic rats (1/13 or 8%).
The slow congenic rats had a higher percentage of tu-
mors with an invasive classification than the rapid con-
genic rats (31% [4/13] vs 11% [2/19]).
Enzymatic activities of recombinant rapid and slow rat
NAT2
PABA N-acetylation velocities for rat arylamine N-ace-
tyltransferase 2 catalyzed by recombinant rapid acetyla-
tor NAT2 was significantly (p = 0.005) higher than by
recombinant slow acetylator NAT2 (Fig. 5a). The folate-
dependent AcCoA hydrolysis catalyzed by rat NAT2 was
significantly (p = 0.005) higher for recombinant rapid
acetylator NAT2 than recombinant slow acetylator
NAT2 (Fig. 5b).
Rapid and slow acetylator rat NAT2 activities in tissue lysates
The PABA N-acetylation activities of Nat2 congenic rats
measured in lysates from several tissue-types was
Fig. 3 Kaplan-Meier plot of palpable mammary tumors in congenic rats. Onset of tumors in rats exposed to a MNU at 3 weeks of age, b MNU at
8 weeks of age, and c DMBA at 8 weeks of age. Squares illustrate rapid and circles illustrate slow acetylator Nat2 congenic rats. Rapid acetylator
congenic rats had a significantly (p<0.05) shorter latency for development of first palpable mammary tumor compared to slow acetylator
congenic rats after MNU administration at either 3 or 8 weeks of age. Similar findings were obtained after DMBA administration at 8 weeks of age
although the difference was not significant (p=0.065)







Total tumors Total tumors
per ratb,c
Total tumors per rat in
tumor- bearing ratsc
MNU 3 weeks Rapid 42 28 (66.7%) 42 1.00 ± 0.17 1.50 ± 0.20
MNU 3 weeks Slow 34 18 (52.9%) 23 0.67 ± 0.12 1.28 ± 0.11
MNU 8 weeks Rapid 24 10 (41.6%)* 12 0.50 ± 0.14* 1.20 ± 0.20
MNU 8 weeks Slow 33 5 (15.2%)* 8 0.24 ± 0.12* 1.60 ± 0.24
DMBA 8 weeks Rapid 25 19 (76.0%)* 30 1.20 ± 0.16** 1.58 ± 0.12
DMBA 8 weeks Slow 30 13 (43.3%)* 17 0.57 ± 0.14** 1.31 ± 0.17
aTumor incidence
bTumor multiplicity
cMean ± SEM. Total mammary tumors differed significantly *(p < 0.05) ** (p < 0.01) between rapid and slow acetylator rats
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significantly higher in rapid than slow acetylator liver
(p < 0.001), lung (p < 0.001), colon (p = 0.007), and
mammary gland (p < 0.001) (Fig. 5c). The folate-
dependent AcCoA hydrolysis was significantly higher in
rapid acetylator than slow acetylator lung (p = 0.002) and
colon (p = 0.002) (Fig. 5d). No detectable folate-
dependent AcCoA hydrolysis activity was observed in liver
and mammary tissue lysates (threshold of detection 0.05
nmoles/min/mg protein).
NAT2 activity and endogenous AcCoA concentrations in
isolated congenic REFs
The REFs isolated from the congenic rat strains were
characterized for their ability to acetylate PABA and
Fig. 4 Photomicrographs of H&E stained slides depicting the criteria utilized to classify tumors. a Normal mammary tissue. b Benign tumor
showing proliferative disease with no cytologic atypia and minimal to no overgrowth of the epithelial or myoepithelial component (black arrows).
c–e CIS lesions with overgrowth of the epithelial and/or myoepithelial component (red arrows). c Low grade CIS lesion with low grade cytologic
atypia and occasional mitoses or single cell apoptosis. d Intermediate grade CIS lesion with intermediate to high grade cytologic atypia with
increased mitoses (blue arrows) or single cell apoptosis. e High grade CIS lesion with intermediate to high grade cytologic atypia with tumor
necrosis (yellow dashed arrow) and increased mitoses (blue arrows). f Invasive carcinoma with glands or single cells infiltrating through stroma
Fig. 5 Rat NAT2 PABA acetylation and folate-dependent AcCoA hydrolysis activity. a, c PABA acetylation activity. b, d Folate-dependent AcCoA
hydrolytic activity. a, b Triplicates from the same recombinant lysates. c, d Lysates of individual tissues collected from 5 rapid (closed bars) or 5
slow (open bars) acetylator NAT2 F344 congenic rats. “ND” = not detectable. Differences between rapid and slow acetylator rats differed significantly
***p < 0.001; **p < 0.01
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their endogenous AcCoA concentrations after the fourth
passage. PABA N-acetylation in rapid NAT2 REFs was
significantly higher than in slow NAT2 REFs (p = 0.002)
(Fig. 6a). Endogenous AcCoA concentrations levels in
the rapid NAT2 REFs were lower compared to that of
the slow NAT2 REFs (p = 0.003) (Fig. 6b).
Discussion
This study is the first to utilize a functional animal
model to look at tumorigenic differences between rapid
and slow rat NAT2 activity using carcinogens that do
not require NAT2 activity for activation/deactivation.
This functional animal model mimics human popula-
tions. Rat NAT2 is the ortholog of human NAT1. Gen-
etic variants and other factors influence human NAT1
activity levels. The NAT1*10 haplotype is associated
with increased NAT1 activity in human tissue samples
[15–17]. Other polymorphic haplotypes encode a less
stable NAT1, leading to a decrease in enzymatic activ-
ity. Our results in Nat2 congenic rats suggest that
human genetic variation resulting in differential NAT1
activity may influence human breast cancer. Further-
more, our findings suggest that NAT1*10 human haplo-
types may have a higher risk of breast cancer compared
to the reference NAT1*4 haplotype. Also, polymorphic
variants that decrease NAT1 activity would likely have
a reduced cancer risk.
In the present study, we investigated whether chemical
carcinogens induced tumors more rapidly or in greater
abundance in rapid than slow Nat2 congenic rat strains.
MNU was administered at either a pre-pubescent age
(3 weeks) or a post-pubescent age (8 weeks). Addition-
ally DMBA was administered at only post-pubescent age
(8 weeks). We observed decreased latency and increased
incidence of palpable mammary tumors in congenic
rapid acetylator rats than in congenic slow acetylator
rats treated with either MNU or DMBA. Terminal
multiplicity and incidence also were higher in rapid than
slow acetylator rats administered MNU or DMBA.
The role of human NAT1 in cancer is not well under-
stood, but the current understanding of NAT1’s potential
importance in cancer is expanding. Several microarray
studies have shown that elevated NAT1 expression is
correlated with estrogen receptor positive (ER+) breast
cancer samples [5, 6, 46]. Human NAT1 expression in
breast cancer is predicted to be a valuable indicator for
antiestrogen responsiveness [47] and an indicator of a
positive prognosis, particularly in ER+ breast cancer [48].
Normal human mammary luminal epithelial cell lines
(HB4a) engineered to overexpress NAT1 continue grow-
ing compared to normal HB4a cells that reach a growth
plateau [5]. The present study adds to the developing and
complex narrative of NAT1 in cancer, by providing the
first animal model data that show an association between
NAT1 activity levels and tumorigenesis independent of
carcinogen metabolism.
Rapid acetylator rats displayed elevated risk of mam-
mary tumors compared to slow acetylator MNU-treated
rats regardless of whether treatment occurred when im-
mature or mature. Pre-pubescent exposure to MNU, re-
gardless of NAT2 activity phenotype, resulted in greater
palpable tumor incidence, as well as increased terminal
mammary tumor incidence and multiplicity (compare
panels in Fig. 3). This increase with earlier age of MNU-
exposure is consistent with the known elevated breast
cancer susceptibility of prepubescent female breasts to
cancer induced by ionizing radiation [49]. MNU, a sim-
ple alkylating agent, is radiomimetic [50]. Humans are
exposed to alkylating chemical carcinogens in diet, to-
bacco products, cosmetics, drugs, and chemotherapy
[51]. The results reported in the current study suggest
that the human NAT1 (an ortholog of rat NAT2) pheno-
type and prepubescent carcinogen exposure should be
studied as additional factors in human breast cancer
susceptibility.
Fig. 6 NAT2 activity and AcCoA level measured in rat embryonic fibroblasts (REFs) from rapid and slow rats. a Rapid NAT2 REFs (N = 7) have a higher
level of PABA acetylation activity than slow NAT2 REFs (N = 9). b The amount of AcCoA per million cells is lower in rapid NAT2 REFs (N = 8) than in
slow NAT2 REFs (N = 10). **Differs significantly between rapid and slow acetylators (p < 0.01)
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The role higher rat NAT2 activity plays in increased
tumorigenesis is poorly understood. Our hypothesis is
that a more active rat NAT2 might lower vital com-
pounds needed for DNA repair to a greater extent than
a less active rat NAT2. Rat NAT2 and human NAT1
are orthologous enzymes that, in addition to their
acetylation capacity, catalyze the hydrolysis of AcCoA
to acetate and coenzyme A in the presence of folate
[43, 52]. Thus, rapid rat NAT2 (or more active human
NAT1) can reduce intracellular levels of AcCoA to a
greater extent than slow rat NAT2, affecting crucial
pathways supporting DNA repair (e.g. histone and p53
acetylation). In support of this hypothesis, measure-
ment of NAT2 activity in rapid acetylator rat tissues
showed higher levels of PABA N-acetylation and folate-
dependent AcCoA hydrolysis than in slow acetylator rat
tissues. These differences were also reflected in recom-
binant rapid and slow acetylator NAT2 expressed in
bacteria. As shown with congenic rat tissues and re-
combinant NAT2 proteins, REFs isolated from rapid
NAT2 rats had a higher PABA N-acetylation activity
level than REFs isolated from the slow NAT2 congenic
rats. Furthermore, rapid NAT2 REFs had lower levels of
AcCoA compared to the slow NAT2 REFs. This obser-
vation parallels the findings with folate-dependent
AcCoA hydrolysis, in that rapid acetylator NAT2 is able
to hydrolyze AcCoA at greater rates than slow acetyla-
tor NAT2 and thus more likely to reduce endogenous
AcCoA levels.
The study of intracellular AcCoA concentration levels
has not been well characterized after DNA insult. Some
studies have shown AcCoA concentrations control cell
growth, cellular autophagy, and histone acetylation
[53–55]. Other studies have shown reduced acetylation
of downstream targets if acetyl-CoA carboxylase, ATP-
citrate lyase, or pantothenate kinase are knocked out
[55–57]. Future studies will further explore human
NAT1 activity in relation to intracellular AcCoA con-
centrations and associated differences in acetylation
targets. Unpublished data from our laboratory suggests
that human NAT1 knockout cancer cell lines have ele-
vated AcCoA concentrations compared to their wild-
type counterparts.
Breast cancer is one of the most common types of
cancer. It is estimated that in 2016 breast cancer will be
the most diagnosed type of cancer in United States
women, excluding basal and squamous cell skin cancers
[58]. It is also expected that breast cancer will be one of
the leading causes of death from cancer in women, with
only lung cancer ranking higher [58]. Breast cancer’s
persistence as one of the most formidable cancers in
women illuminates the need to understand differences
in cancer susceptibility and discover novel avenues for
prevention and treatment. The studies in this paper
primarily focus on breast cancer. However given ubiqui-
tous expression of NAT1, the findings here are likely to
be observed in other cancer sites such as lung, colon,
urinary bladder, and prostate.
Conclusions
In summary, we report differences in mammary tumor in-
cidence and multiplicity between rapid and slow acetylator
congenic F344.WKY-Nat2 rats following administration of
a direct acting carcinogen (MNU) and pro-carcinogen
(DMBA). Rat NAT2 does not metabolize these carcino-
gens. We have shown that folate-dependent AcCoA hy-
drolysis is higher in rapid compared to slow acetylator rat
NAT2, both in recombinant form and in tissue lysates
from multiple organs. Additionally, we provided the first
evidence that rat NAT2 plays a role in modulating intra-
cellular AcCoA concentrations. Our findings suggest that
further study of a role for human NAT1 in cancer suscep-
tibility apart from the role of NAT1 in carcinogen metab-
olism is warranted.
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